CAMBRIDGE, Mass., Feb. 22 /PRNewswire-FirstCall/ -- Hybridon, Inc. announced today that Sudhir Agrawal, D. Phil, Hybridon's President, Chief Executive Officer, and Chief Scientific Officer, will present an overview of the Company's discovery and drug development programs at the 2005 BIO CEO and Investor Conference. The presentation will take place at 3:30 PM at the Waldorf-Astoria in New York on Thursday, February 24, 2005.
The presentation can be accessed via a live webcast on the webcasts page of Hybridon's website: http://www.hybridon.com/webcasts.php
An archived version of the webcast will be available two hours after the live webcast, and remain active through Saturday, March 19th, 2005, on Hybridon's website and the BIO CEO website.
Hybridon, Inc. is developing novel therapeutics based on synthetic nucleic acids for the treatment of cancer, asthma/allergies, and infectious diseases. Hybridon's proprietary drug candidates are designed to modulate immune responses through Toll-like receptor 9. The Company's nucleic acid chemistry expertise has generated a broad portfolio of intellectual property, partnered products and licenses, creating long-term value for Hybridon. For more information please visit our website at http://www.hybridon.com/.
Hybridon, Inc. Euro RSCG Life NRP
617-679-5500, x 5517 212-845-4268
Robert G. Andersen Robert Stanislaro (media)
Brian Ritchie (investors
CONTACT: Robert G. Andersen of Hybridon, Inc., +1-617-679-5500, x 5517,email@example.com; or Robert Stanislaro (media), +1-212-845-4268, orBrian Ritchie (investors), +1-212-845-4269, both of Euro RSCG Life NRP, forHybridon, Inc.